5.69
+6.55%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BIOAGE Labs
From its filings with the US Securities and Exchange Commission
BIOAGE Labs is based in Emeryville, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BIOA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $9.0m and a net loss of $80.6m. At that date it held total assets of $294.9m and shareholders' equity of $272.1m.
We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.
In January 2025, we announced the nomination of our lead program, BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor. BGE-102 has a distinct mechanism and binding site from other NLRP3 inhibitors in development with issued patents covering both composition of matter and claims for the unique binding site.
In December 2025, we announced that BGE-102 was well-tolerated in Single Ascending Dose (SAD) and initial Multiple Ascending Dose (MAD) cohorts, with a pharmacokinetic profile supporting once-daily oral dosing, strong target engagement and high brain penetration.
We intend to advance BGE-102 in two therapeutic areas: cardiometabolic disease and ophthalmology.
Our first therapeutic area for BGE-102 is cardiometabolic disease, with a focus on atherosclerotic cardiovascular disease (ASCVD) risk reduction. Chronic systemic inflammation, as measured by high-sensitivity C-reactive protein (hsCRP), is an independent risk factor for cardiovascular events that is not adequately addressed by current lipid-lowering and antihypertensive therapies. In January 2026, we announced additional positive interim Phase 1 data, demonstrating potential for best-in-class hsCRP reduction in participants with elevated cardiovascular risk.
Quoted from its 10-K, filed 24 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 26 Sept 2024
- Employees
- 60
- Website
- bioagelabs.com ↗
- Head office
- 5885 HOLLIS STREET, EMERYVILLE, CA, 94608
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Jean-Pierre GarnierIndependent Chairman of the Board$1.5m
- Dr. Kristen FortneyPresident, Chief Executive Officer, Director, since 2015$12.2m
- Dr. Dov GoldsteinChief Financial Officer
- Dr. Eric MorgenChief Operating Officer, Director, since 2017$2.5m
- Dr. Paul RubinChief Medical Officer$1.9m
- Dr. Michael DavidsonIndependent Director$492,400
- Mr. Patrick EnrightIndependent Director$231,098
- Dr. James HealyIndependent Director$233,339
- Ms. Rekha HemrajaniIndependent Director$464,969
- Dr. Vijay PandeIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 16
- Environment
- 17
- Social
- 16
- Governance
- 14
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company operates in the Pharmaceuticals sector with a focus on metabolic diseases.
- Lead product candidate azelaprag has shown positive results in Phase Ib trials.
- Company has initiated Phase II trials for azelaprag in combination with tirzepatide.
Weaknesses
- Company has only 60 employees, indicating limited resources.
- IPO is scheduled for 2024-09-26, suggesting early-stage financial structure.
- Company is clinical-stage, meaning products are not yet commercially available.
Opportunities
- Potential for azelaprag to be used as an oral regimen with incretin drugs for obesity therapy.
- Development of NLRP3 inhibitors for neuroinflammation diseases presents new market potential.
- Preclinical programs based on human longevity data could lead to innovative treatments.
Threats
- Clinical-stage status increases risk of trial failures or delays.
- Competition in the pharmaceutical industry for obesity and metabolic disease treatments.
- Dependence on successful clinical trials for product approval and market entry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.